<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Octtaviani E</submitter><funding>NIGMS NIH HHS</funding><pagination>5275-86</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC1679690</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17(12)</volume><pubmed_abstract>Cytokinesis requires a complex network of equatorial and global proteins to regulate cell shape changes. Here, using interaction genetics, we report the first characterization of a novel protein, enlazin. Enlazin is a natural fusion of two canonical classes of actin-associated proteins, the ezrin-radixin-moesin family and fimbrin, and it is localized to actin-rich structures. A fragment of enlazin, enl-tr, was isolated as a genetic suppressor of the cytokinesis defect of cortexillin-I mutants. Expression of enl-tr disrupts expression of endogenous enlazin, indicating that enl-tr functions as a dominant-negative lesion. Enlazin is distributed globally during cytokinesis and is required for cortical tension and cell adhesion. Consistent with a role in cell mechanics, inhibition of enlazin in a cortexillin-I background restores cytokinesis furrowing dynamics and suppresses the growth-in-suspension defect. However, as expected for a role in cell adhesion, inhibiting enlazin in a myosin-II background induces a synthetic cytokinesis phenotype, frequently arresting furrow ingression at the dumbbell shape and/or causing recession of the furrow. Thus, enlazin has roles in cell mechanics and adhesion, and these roles seem to be differentially significant for cytokinesis, depending on the genetic background.</pubmed_abstract><journal>Molecular biology of the cell</journal><pubmed_title>Enlazin, a natural fusion of two classes of canonical cytoskeletal proteins, contributes to cytokinesis dynamics.</pubmed_title><pmcid>PMC1679690</pmcid><funding_grant_id>R01 GM066817-01A1</funding_grant_id><funding_grant_id>R01 GM066817</funding_grant_id><funding_grant_id>R01 GM066817-03</funding_grant_id><funding_grant_id>R01 GM066817-02</funding_grant_id><funding_grant_id>R01 GM066817-04</funding_grant_id><funding_grant_id>R01 GM-066817</funding_grant_id><pubmed_authors>Effler JC</pubmed_authors><pubmed_authors>Robinson DN</pubmed_authors><pubmed_authors>Octtaviani E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Enlazin, a natural fusion of two classes of canonical cytoskeletal proteins, contributes to cytokinesis dynamics.</name><description>Cytokinesis requires a complex network of equatorial and global proteins to regulate cell shape changes. Here, using interaction genetics, we report the first characterization of a novel protein, enlazin. Enlazin is a natural fusion of two canonical classes of actin-associated proteins, the ezrin-radixin-moesin family and fimbrin, and it is localized to actin-rich structures. A fragment of enlazin, enl-tr, was isolated as a genetic suppressor of the cytokinesis defect of cortexillin-I mutants. Expression of enl-tr disrupts expression of endogenous enlazin, indicating that enl-tr functions as a dominant-negative lesion. Enlazin is distributed globally during cytokinesis and is required for cortical tension and cell adhesion. Consistent with a role in cell mechanics, inhibition of enlazin in a cortexillin-I background restores cytokinesis furrowing dynamics and suppresses the growth-in-suspension defect. However, as expected for a role in cell adhesion, inhibiting enlazin in a myosin-II background induces a synthetic cytokinesis phenotype, frequently arresting furrow ingression at the dumbbell shape and/or causing recession of the furrow. Thus, enlazin has roles in cell mechanics and adhesion, and these roles seem to be differentially significant for cytokinesis, depending on the genetic background.</description><dates><release>2006-01-01T00:00:00Z</release><publication>2006 Dec</publication><modification>2024-11-15T19:13:13.239Z</modification><creation>2019-03-27T01:46:20Z</creation></dates><accession>S-EPMC1679690</accession><cross_references><pubmed>17050732</pubmed><doi>10.1091/mbc.e06-08-0767</doi></cross_references></HashMap>